Compare Cassava Sciences Inc (FLNA) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nutrien Ltd — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Nutrien Ltd trades at $66.92 (market cap $32.46B). The key difference: Nutrien Ltd is far larger — about 610.8× Cassava Sciences Inc's market cap, and Nutrien Ltd pays a 3.22% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NTR | |
|---|---|---|
Market Cap | $53.14M | $32.46B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $83.94 |
52-Week Low | $1.09 | $53.64 |
Enterprise Value | -$33.43M | $45.62B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Nutrien (NTR) trades at $68.64, up 1.54% today, with a bullish technical outlook and strong analyst support. The stock shows solid fundamentals with a P/E of 13.92 and net income margin of 8.58%, while recent earnings beat expectations in two of the last three quarters. Healthy fertilizer demand and cost controls support growth, though input cost pressures persist.
Outlook remains positive with a consensus price target of $77.67, offering 13% upside. Key risks include volatile input costs and industry headwinds, but institutional buy ratings (63.6%) and stable cash flows provide a foundation for continued shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
